Rim enhancement on hepatobiliary phase of pre-treatment 3.0T MRI: a potential marker for early chemotherapy response in colorectal liver metastases treated with XELOX

2021 ◽  
pp. 109887
Author(s):  
Xinxin Wang ◽  
Yu Wang ◽  
Ziqian Zhang ◽  
Meng Zhou ◽  
Xueyan Zhou ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Chemotherapy Response ◽  
Hepatobiliary Phase ◽  
Potential Marker ◽  
Rim Enhancement ◽  
Pre Treatment ◽  
3.0T Mri

scholarly journals FIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATION

2015 ◽  
Vol 28 (4) ◽  
pp. 222-230 ◽  
Author(s):  
Felipe José Fernandez COIMBRA ◽  
Heber Salvador de Castro RIBEIRO ◽  
Márcio Carmona MARQUES ◽  
Paulo HERMAN ◽  
Rubens CHOJNIAK ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Liver Metastases ◽  
Multimodal Treatment ◽  
Colorectal Liver Metastases ◽  
Epidemiological Data ◽  
Treatment Modalities ◽  
Established Method ◽  
Curative Intent ◽  
Pre Treatment ◽  
Definition Of

Background : Liver metastases of colorectal cancer are frequent and potentially fatal event in the evolution of patients with these tumors. Aim : In this module, was contextualized the clinical situations and parameterized epidemiological data and results of the various treatment modalities established. Method: Was realized deep discussion on detecting and staging metastatic colorectal cancer, as well as employment of imaging methods in the evaluation of response to instituted systemic therapy. Results : The next step was based on the definition of which patients would have their metastases considered resectable and how to expand the amount of patients elegible for modalities with curative intent. Conclusion : Were presented clinical, pathological and molecular prognostic factors, validated to be taken into account in clinical practice.

scholarly journals FDG-PET Improves Management of Patients with Colorectal Liver Metastases Allocated for Local Treatment: A Consecutive Prospective Study

2007 ◽  
Vol 96 (3) ◽  
pp. 209-213 ◽  
Author(s):  
M. Sørensen ◽  
F. V. Mortensen ◽  
M. Høyer ◽  
H. Vilstrup ◽  
S. Keiding ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Fdg Pet ◽  
Colorectal Liver Metastases ◽  
Imaging Modality ◽  
Treatment Plan ◽  
Local Treatment ◽  
Liver Lesions ◽  
Term Survival ◽  
Pre Treatment

Background and Aim: Colorectal cancer is a common cancer in the Nordic countries and 50% of the patients develop liver metastases. Liver resection may result in long term survival. Proper staging is therefore essential and CT is the standard imaging modality. We examined whether additional FDG-PET improves therapeutic management of patients with colorectal liver metastases. Patients and Methods: Fifty-four consecutive patients were enrolled. Each patient had a treatment plan made based on our standard evaluation. The patients then had a PET scan and the treatment plan was re-evaluated, taking these results into account. Results: In 76% of the cases, PET did not change the treatment plan due to complete concordance with CT. In another 19% of the cases, the plan was altered due to finding of more liver lesions by PET than by CT (four patients), fewer or no liver lesions (three patients), and extrahepatic lesions not visible on CT (three patients). In 5% of the cases, non-concordance between PET and CT did not change the therapeutic plan. Conclusion: Pre-treatment FDG-PET, used supplementary to CT, improved the treatment plan in one fifth of the patients with colorectal liver metastases.

Pathologic indicators of chemotherapy response in colorectal liver metastases: A comparative study.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e14159-e14159
Author(s):  
J. Maresch ◽  
S. Stremitzer ◽  
D. Tamandl ◽  
F. Wrba ◽  
T. Gruenberger
Keyword(s):  
Comparative Study ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Chemotherapy Response

scholarly journals Chemotherapy Response Monitoring of Colorectal Liver Metastases by Dynamic Gd-DTPA-Enhanced MRI Perfusion Parameters and 18F-FDG PET Metabolic Rate

2009 ◽  
Vol 50 (11) ◽  
pp. 1777-1784 ◽  
Author(s):  
D. Vriens ◽  
H. W.M. van Laarhoven ◽  
J. J.A. van Asten ◽  
P. F.M. Krabbe ◽  
E. P. Visser ◽  
...  
Keyword(s):  
Metabolic Rate ◽  
Liver Metastases ◽  
Fdg Pet ◽  
Colorectal Liver Metastases ◽  
Response Monitoring ◽  
Chemotherapy Response ◽  
Enhanced Mri ◽  
18F Fdg

Histological growth pattern as a potential marker of oligometastatic disease in patients operated for colorectal liver metastases.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15093-e15093
Author(s):  
Ali Bohlok ◽  
Robin Dezes ◽  
Valerio Lucidi ◽  
Fikri Bouazza ◽  
Desislava Germanova ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Growth Pattern ◽  
Prognostic Value ◽  
Colorectal Liver Metastases ◽  
Surrogate Marker ◽  
Oncological Outcome ◽  
International Consensus ◽  
Dominant Phenotype ◽  
Potential Marker ◽  
Surgical Data

e15093 Background: The identification of oligometastatic profile in patients with resectable colorectal liver metastases (CRLM) would represent a major progress to improve selection for surgery. Currently, in the absence of biomarkers, the most reliable method to identify oligometastatic (OLM) and non-oligometastatic (NOLM) tumors relies on the oncological outcome after metastases-targeted surgery. The histological growth pattern (HGP) of CRLM, defined as desmoplastic (dHGP) or replacement (rHGP), has recently been shown to have prognostic value. We analyzed HGP in a series of patients operated for CRLM, characterized as OLM in case of prolonged postoperative recurrence-free survival (RFS) or NOLM in case of rapid postoperative relapse. Methods: In 357 patients operated for CRLM, we identified OLM patients as those with RFS≥5 years (N = 64), and NOLM patients as those with RFS < 1 year (N = 77). Clinicopathologic and surgical parameters were analyzed. In each CRLM, HGP was assessed in archival H&E stained tissue sections, according to international consensus guidelines. Proportions of rHGP and dHGP were determined in each metastasis. In case of multiple metastases, the mean HGP was calculated in each patient. Patients were categorized as pure (> 95% rHGP or dHGP) or dominant phenotypes (> 50% rHGP or dHGP, of the entire tumor-liver interface). Results: Preoperative characteristics of primary tumor and CRLM, and surgical data were identical in OLM and NOLM groups. In a first set of analyses, HGP was determined in 39 OLM and 52 NOLM patients. Pure dHGP was observed in 54.3% of OLM and 17.3% of NOLM patients (p = 0.001). Pure rHGP was similarly distributed among OLM and NOLM groups. Sixty-nine% of the OLM patients displayed a dHGP-dominant phenotype, whereas 57.7% of the NOLM patients presented with a rHGP-dominant phenotype (p = 0.02). Conclusions: These results confirm the potential prognostic value of HGP in patients operated for CRLM. dHGP, associated with angiogenesis and inflammation, could represent a (surrogate) marker for oligometastatic progression, whereas rHGP appears strongly associated with rapid postoperative relapse.

scholarly journals Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Vincenza Granata ◽  
Roberta Fusco ◽  
Francesca Maio ◽  
Antonio Avallone ◽  
Guglielmo Nasti ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Mean Value ◽  
Qualitative Assessment ◽  
Colorectal Metastases ◽  
Arterial Phase ◽  
Hepatobiliary Phase ◽  
Portal Phase ◽  
Surgical Setting ◽  
Contrast Studies

Abstract Aim To compare liver-specific EOB-GD-DTPA and liver-non-specific Gd-BT-DO3A MR, in hepatocellular carcinoma (HCC) and liver colorectal metastases. Material and methods Seventy HCC patients with 158 nodules and 90 colorectal liver metastases (mCRC) with 370 lesions were included in the retrospective analysis. HCC patients underwent MR at 0 time (MR0), after 3 (MR3) and 6 months (MR6) using two different CM; 69 mCRC patients underwent MR with Gd-EOB-BTPA and 21 mCRC patients with Gd-BT-DO3A. We evaluated arterial phase hyperenhancement, lesion-to-liver contrast during portal phase, hepatobiliary phase parenchymal hyperenhancement. Results In HCC patients arterial phase hyperenhancement degree was statistically higher (p = 0.03) with Gd-BT-DO3A (mean 4) than GD-EOB-DTPA (mean 2.6), while we found no significant statistical differences among mean (2.6) values at MR0 and MR6 using GD-EOB-DTPA. For all 209 patients underwent Gd-EOB-DTPA, we found that lesion-to-liver contrast during portal phase mean value was 4 while for patients underwent MR with Gd-BT-DO3A was 3 (p = 0.04). For HCC hepatobiliary phase parenchymal hyperenhancement mean value was 2.4. For mCRC patients: among 63 patients underwent previous chemotherapy hepatobiliary phase parenchymal hyperenhancement mean value was 3.1 while for 6 patients no underwent previous chemotherapy was 4 (p = 0.05). Conclusions Gd-EOB-DTPA should be chosen in pre surgical setting in patients with colorectal liver metastases.

The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA “uptake” on the hepatobiliary phase of MR imaging

2015 ◽  
Vol 40 (7) ◽  
pp. 2364-2371 ◽  
Author(s):  
Vincenza Granata ◽  
Orlando Catalano ◽  
Roberta Fusco ◽  
Fabiana Tatangelo ◽  
Daniela Rega ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Liver Metastases ◽  
Colorectal Liver Metastases ◽  
Hepatobiliary Phase ◽  
Target Sign
Sign in / Sign up

Export Citation Format

Share Document